Moreover, PVR, IDO, MHCII, and TIM3 are potential new targets in SCLC with increased expression in NE‐low subtype, providing critical insight for further prospective studies on SCLC immunotherapies. This evidence concerns the gene HAVCR2 and small cell lung carcinoma.